Targeting survival pathways in chronic myeloid leukaemia stem cells
about
Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentMitochondrial Dysfunction in Human Leukemic Stem/Progenitor Cells upon Loss of RAC2Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemiaTyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.Translational regulation of GPx-1 and GPx-4 by the mTOR pathway.Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABLTargeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.Hypoxia-Like Signatures Induced by BCR-ABL Potentially Alter the Glutamine Uptake for Maintaining Oxidative PhosphorylationDipeptide species regulate p38MAPK-Smad3 signalling to maintain chronic myelogenous leukaemia stem cells.Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells.Investigating evolutionary perspective of carcinogenesis with single-cell transcriptome analysis.Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development.Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules.Update on emerging treatments for chronic myeloid leukemia.Novel drug therapies in myeloid leukemia.Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.Immunological Analyses of Leukemia Stem Cells.Emerging therapeutic aspects in oncology.Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.New hope for chronic myelogenous leukemia patients: dasatinib offers better efficacy with shorter treatment.Detecting Autophagy and Autophagy Flux in Chronic Myeloid Leukemia Cells Using a Cyto-ID Fluorescence Spectrophotometric Assay.A large-scale RNA interference screen identifies genes that regulate autophagy at different stages.Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment.Total Synthesis of Δ(12) -Prostaglandin J3 : Evolution of Synthetic Strategies to a Streamlined Process.Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.The Wave2 scaffold Hem-1 is required for transition of fetal liver hematopoiesis to bone marrow.
P2860
Q26766299-96AFC318-3D57-49D5-B9A5-70BC8C97AF02Q27305153-12DD596F-BC4B-4589-9E0C-031298346773Q28081844-F47008DF-8508-4784-BA2E-02C6B9E2D75BQ33728096-58FAD7C9-1B20-47D2-B587-2DE3D9D52351Q34272962-7C63F3DA-C358-4576-9ABC-9BC6ADF773A1Q35137710-6581C234-6514-4612-B0FE-2484133A1FF9Q35596540-EC3CC134-8F18-4246-8FB4-370DE58AEC4AQ35727453-8E76ECD7-9B2E-4E4B-8578-4338727FD925Q35931271-05D0CA89-1FEE-4015-A11A-D8E54570DF49Q35982752-1E9050D7-86DE-4506-A35A-BE2357A2D211Q36030083-D923EF7F-5FCD-4DD2-9B9E-3A4198254071Q36622106-E74313EE-5CBF-495F-98EE-454E6F991A15Q37409760-2E04B5C7-B644-4F65-8E42-1C73985184E9Q37662286-6CA3EB32-DEA2-471B-A75F-4CECD669CD81Q38175044-4F1E72C1-0F87-4292-BE99-C9CD9F562E06Q38262877-324C64CE-9CB5-4FC4-ABB2-930D957E838DQ38397515-F1487AFB-46F4-4BB2-A345-EB618179555DQ38510486-95266B5D-181C-4E84-BD42-AACE55C52BF5Q38743474-483027DE-E850-4C16-8978-59112860C7ECQ38825799-19845348-BD7F-4A25-8A5E-01C6429D07D6Q39377645-2A716C2E-9F37-434F-938A-C2902D1D3F56Q42070616-0210DF8F-6CB6-4DD7-8E8F-BBE630A3B82EQ42407714-B91603C1-2B35-4852-B093-7C844C5A0D84Q45041456-24A4043D-D48E-4DB4-B67D-240D35ADED6BQ50055572-767A4FAB-C13B-4383-9C11-21AFA36F6E8BQ50123249-57BA5D50-47E2-42D6-9624-4E580B45237EQ50852528-D00DE267-1CED-473E-A1C7-70A042D4030EQ54117733-D34E7336-E6DB-463C-AEDB-DC09AFAEA154Q54978822-CD370514-3DD7-4D9F-B2BD-3BA4833F87D1Q55395798-5FCB16CB-48E4-469B-A989-578B7CFEA271
P2860
Targeting survival pathways in chronic myeloid leukaemia stem cells
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting survival pathways in chronic myeloid leukaemia stem cells
@en
Targeting survival pathways in chronic myeloid leukaemia stem cells.
@nl
type
label
Targeting survival pathways in chronic myeloid leukaemia stem cells
@en
Targeting survival pathways in chronic myeloid leukaemia stem cells.
@nl
prefLabel
Targeting survival pathways in chronic myeloid leukaemia stem cells
@en
Targeting survival pathways in chronic myeloid leukaemia stem cells.
@nl
P2860
P356
P1476
Targeting survival pathways in chronic myeloid leukaemia stem cells
@en
P2093
P2860
P304
P356
10.1111/BPH.12183
P407
P577
2013-08-01T00:00:00Z